Morning Briefing
Summaries of health policy coverage from major news organizations
Molnupiravir May Be Triggering Covid Mutations; New FDA Guidance On Antibiotics In Food Animals
A new paper suggests scientists are worried about molnupiravir's capacity to trigger SARS-CoV-2 mutations, echoing concerns that were raised even before countries approved it for emergency use in late 2021 as the Omicron variant arrived on the scene. (Schnirring, 9/26)
The US Food and Drug Administration (FDA) today published draft guidance for defining appropriate duration of use in antibiotics used in the feed of food-producing animals. (Dall, 9/26)
Detection of the BRAF V600E mutation in pediatric low-grade glioma has been associated with a lower response to standard chemotherapy. In previous trials, dabrafenib (both as monotherapy and in combination with trametinib) has shown efficacy in recurrent pediatric low-grade glioma with BRAF V600 mutations, findings that warrant further evaluation of this combination as first-line therapy. (Bouffet, M.D., et al, 9/21)
